Henry Ford Health enrolled the first U.S. patients in a global pulmonary artery denervation clinical trial evaluating the procedure in pulmonary hypertension related to heart disease. The enrollment marks the first U.S. site activity in the multi-region study. Pulmonary artery denervation aims to modulate sympathetic signaling believed to contribute to disease physiology. The trial’s global design suggests data will be pooled across sites to assess efficacy and safety with consistent procedural and follow-up frameworks. For pulmonary hypertension developers and interventional teams, early U.S. enrollment is a key milestone that can affect patient referral patterns and future adoption if outcomes support benefit. The study also offers a practical checkpoint on operator experience and standardized catheter-based workflows in real-world U.S. settings.